>





A naturally-occurring copper-binding tripeptide (Gly-His-Lys) supplied as a 1:1 Cu²⁺ complex. Studied for collagen synthesis, antioxidant activity, and skin-repair pathways.
GHK-Cu is the copper(II) complex of the tripeptide Gly-His-Lys, originally identified in human plasma. It is investigated for upregulation of collagen and glycosaminoglycan synthesis, antioxidant activity, and modulation of fibroblast and stem-cell behavior in dermal-repair models.
Each vial is lyophilized from a buffered solution, sealed under nitrogen, and shipped cold-chain at −20 °C from our Kelowna facility.
Fibroblast collagen and elastin synthesis assays, antioxidant capacity screens, in-vitro wound-closure (scratch) assays, hair-follicle dermal-papilla cell models, and copper-chelation comparative studies.
Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.
| Parameter | Value |
|---|---|
| Sequence | Gly-His-Lys (with Cu²⁺ bound to histidine imidazole + amide nitrogens) |
| Molecular formula | C₁₄H₂₄CuN₆O₄ |
| Molecular weight | 403.94 g/mol |
| CAS number | 49557-75-7 |
| Length | Tripeptide-copper complex |
| Test | Specification |
|---|---|
| HPLC purity | ≥ 99.0% (lot LM-2640: 99.18%) |
| Mass confirmation | ESI-MS within 0.5 Da |
| Net peptide content | ≥ 80% by AAA |
| Endotoxin | < 0.5 EU/mg (LAL) |
| Bioburden | < 10 CFU/g |
| Residual TFA | < 1.0% |
Manufactured 04 Mar 2026 · Released 11 Mar 2026 · Tested by Lumera QC, Kelowna BC. Retain samples held under storage spec for five years from release date.
| Method | Result |
|---|---|
| RP-HPLC at 220 nm | 99.18% main peak |
| ESI-MS (positive) | 403.9 Da (theor. 403.94) |
| Amino acid analysis | 82.1% net peptide |
| LAL endotoxin | < 0.05 EU/mg |
| Karl Fischer (water) | 2.8% w/w |
Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0–2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.
Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.
Reconstituted solution is stable for 28 days at 2–8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.
Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide. Int J Mol Sci. 2018;19(7):1987.
Maquart FX et al. Stimulation of collagen synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. FEBS Lett. 1988;238(2):343–346.
Pickart L et al. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging. Biomed Res Int. 2012;2012:324832.
GHK-Cu reference standard, ≥99% (HPLC), Lumera Labs Inc., Cat. No. LUM-GHKCU-50, Lot 26-A031.
Ghk Cu is a copper-binding tripeptide, classified within the wound-repair signaling pathway. Structurally it is a Gly-His-Lys + Cu²⁺ chelation complex. GHK-Cu is a copper-bound tripeptide naturally present in plasma at higher concentrations in young adults than in older ones. Pickart and Margolina (2018) characterized its broad signal-modulating effects on fibroblast proliferation, collagen synthesis, and antioxidant gene expression.
In an in-vitro setting, Ghk Cu interacts with its target receptor(s) at low-nanomolar affinities under standard binding-assay conditions. Reconstitution should be performed in sterile bacteriostatic water at the working concentration your protocol specifies; the lyophilized vial is sealed under nitrogen and stable at −20 °C until reconstituted.
Ghk Cu arrives lyophilized at −20 °C in cold-chain insulated packaging. On receipt, transfer immediately to a −20 °C freezer. Once reconstituted, store at 2-8 °C and use within the window noted on the lot's COA. Avoid repeated freeze-thaw cycles.
For laboratory research only. Ghk Cu is sold strictly as an in-vitro reference standard. It is not approved for human or veterinary use by Health Canada or the FDA.